CD44-Targeted Nanocarrier for Cancer Therapy

Area of Science:

• Oncology
• Biomedical Engineering
• Nanotechnology

Background:

• Cluster of differentiation 44 (CD44) is a cell surface glycoprotein overexpressed in numerous solid tumors, playing roles in proliferation, migration, and immune responses.
• CD44 exhibits selective binding affinity for hyaluronic acid and chondroitin sulfate, making it a potential target for cancer therapy.

Purpose of the Study:

• To review the role of CD44 in cancer and its therapeutic targeting using various nanocarriers.
• To explore the application of nanocarriers for targeted delivery of chemotherapeutic agents and nucleic acids to CD44-overexpressing cancer cells.
• To highlight the significance of hyaluronic acid in cancer therapy and its interaction with CD44.

Main Methods:

• Review of existing literature on CD44 function in cancer.
• Analysis of nanocarrier systems (nanoparticles, dendrimers, micelles, etc.) for CD44-targeted drug delivery.
• Examination of hyaluronic acid's role and interaction with CD44 in therapeutic strategies.

Main Results:

• CD44 overexpression is a hallmark of various solid tumors, indicating its potential as a therapeutic target.
• Nanocarriers offer effective platforms for delivering chemotherapeutics and nucleic acids to CD44-positive cancer cells.
• Hyaluronic acid-based strategies demonstrate promise in targeting CD44-overexpressed neoplastic cells.

Conclusions:

• Targeting CD44 with nanocarriers, particularly those utilizing hyaluronic acid, represents a promising strategy for enhancing chemotherapy efficacy.
• Precision chemotherapy can be achieved by controlling the release, uptake, and accumulation of therapeutic agents via CD44 targeting.
• Further research into CD44-targeted nanomedicine holds significant potential for advancing cancer treatment.